Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer

NCT05044871 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

108

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Pamiparib
DRUG: Bevacizumab
DRUG: Tislelizumab
DRUG: Nab paclitaxel
DRUG: Bevacizumab + Nab paclitaxel (intense dose-dense)

Sponsor

Tongji Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]